Nearly 100,000 Americans Estimated to be Diagnosed with Melanoma in 2023
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for cancer in the United States.
Registration Now Open: MRA's 2023 Patient Forum
Registration for MRA's Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on Wednesday, March 8, is now open. Register now to hear from leading experts in the melanoma field and have the opportunity to ask questions, discuss, and network with other people who are going through their own melanoma journey.
Overcoming Melanoma Treatment Resistance Research Update
About half of all patients given cancer immunotherapies do not respond to them, and although targeted therapies often dramatically shrink tumors in most patients, in about three-quarters of those patients, the treatments stop being effective weeks to months after initially killing tumor cells.
MRA's Latest Research Report: The Melanoma Research Community Reunites
Each year, MRA brings together hundreds of people from across the melanoma research community to exchange ideas, report on scientific progress, celebrate achievements, and mourn our collective losses.
What Uveal Melanoma Patients Need to Know about KIMMTRAK
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 18 July 2022 In Science, Treatment
You may have heard of KIMMTRAK, a new therapy that recently earned FDA approval for the treatment of metastatic or unresectable uveal melanoma. Uveal melanoma, also called ocular melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. KIMMTRAK is the first drug to earn FDA approval to treat these patients.
What Melanoma Patients Need to Know about Opdualag
You may have heard of Opdualag, a new therapy that recently earned FDA approval for advanced melanoma. Opdualag, which combines two different immunotherapies into one medicine, is earning attention as an effective – and more easily tolerated – combination therapy.
MRA Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 19 May 2022 In News, Prevention, Science, Treatment
Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment.
Dr. Gary Deng & The Wellness Principles
Gary Deng, MD, PhD – an integrative medicine specialist at Memorial Sloan Kettering Cancer Center – knows this firsthand. And now, for the first time, Dr. Deng is sharing his unique and highly respected wellness approach with everyone through his upcoming book, The Wellness Principles – Cooking for a Healthy Life.
Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment
It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.
MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma
The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.